Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms.
- Author:
Luohai CHEN
;
Minhu CHEN
;
Jie CHEN
1
Author Information
1. Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. chen0jie@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Biomarkers, Tumor;
blood;
Chromogranin A;
blood;
Chromogranin B;
blood;
chemistry;
Gastrointestinal Neoplasms;
blood;
chemistry;
diagnosis;
genetics;
Humans;
MicroRNAs;
blood;
Neoplastic Cells, Circulating;
Neuroendocrine Tumors;
blood;
chemistry;
diagnosis;
genetics;
Pancreatic Neoplasms;
blood;
chemistry;
diagnosis;
genetics;
Pancreatic Polypeptide;
blood;
Phosphopyruvate Hydratase;
blood
- From:
Chinese Journal of Gastrointestinal Surgery
2017;20(3):357-360
- CountryChina
- Language:Chinese
-
Abstract:
Gastroenteropancreatic neuroendocrine neoplam (GEP-NEN) is a rare group of tumors with its incidence rising significantly in recent decades. Because of the late presentation of the disease and limitations in conventional biomarkers, about 50% of GEP-NEN patients manifests advanced disease when diagnosed. Therefore, it is vital to identify circulating biomarkers which can not only be used for early diagnosis but also accurately evaluating the biological behavior of GEP-NEN. This review summarizes the advances of circulating biomarkers in diagnosing and evaluating efficacy of treatment in GEP-NEN. Well-known circulating biomarkers include chromogranin A (CgA), pancreastatin (PST), chromogranin B (CgB), neuron-specific enolase (NSE) and pancreatic peptide(PP). Novel biomarkers including circulating tumor cell(CTC), microRNA and NETest are promising biomarkers with potential clinical benefit, but further researches are needed before their clinical applications.
